[144] Alnylam Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filing for Alnylam Pharmaceuticals (ALNY) discloses a proposed sale of 3,474 shares of Common stock through UBS Financial Services on NASDAQ with an aggregate market value of $1,571,012 and 131,079,015 shares outstanding. The securities were acquired as performance stock units: 1,673 shares on 06/24/2024 and 1,801 shares on 04/26/2023, with payment dates matching acquisition dates. The filer reports Nothing to Report for securities sold in the past three months and includes the customary representation that they do not possess undisclosed material adverse information. The notice is procedural under Rule 144 to report an intended sale.

Positive

• Clear disclosure of broker, planned sale date, share count, and aggregate market value
• Securities were acquired as PSUs, indicating compensation origin rather than third-party transfer
• No reported sales in the prior three months, simplifying aggregation rules
• Filer attests to absence of undisclosed material adverse information, consistent with Rule 144 requirements

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider notice; small share sale relative to float, unlikely to materially affect company valuation.

The Form 144 reports a planned sale of 3,474 common shares valued at $1.57M. Versus 131.08M shares outstanding this position is immaterial to capital structure or market liquidity. The shares were issued as PSUs in 2023 and 2024, indicating compensation-related disposition rather than operational or strategic changes. Because no sales occurred in the prior three months and the filer attests to no undisclosed material information, this is a standard disclosure event and presents limited informational impact for investors.

Compliance/Risk Analyst

TL;DR: Filing appears procedurally compliant with Rule 144 and includes required attestations; no red flags in the disclosed fields.

The notice identifies broker, planned sale date, share counts, acquisition dates and nature of acquisition (PSU). It states no reportable sales in the past three months and contains the signers representation about material nonpublic information. Absent contradictory data, the filing meets disclosure requirements and signals adherence to insider-sale reporting protocols. No compliance irregularities are evident from the provided content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010	3474	1571012.00	131079015	08/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/24/2024	PSU	Issuer			1673	06/24/2024	N/A
Common	04/26/2023	PSU	Issuer			1801	04/26/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for ALNY disclose about the proposed sale?

The filing discloses a proposed sale of 3,474 common shares through UBS on NASDAQ for an aggregate market value of $1,571,012, with an approximate sale date of 08/29/2025.

How many shares outstanding does Alnylam report in the Form 144?

The filing lists 131,079,015 shares outstanding.

When and how were the shares to be sold acquired according to the filing?

The securities were acquired as PSUs: 1,673 shares on 06/24/2024 and 1,801 shares on 04/26/2023.

Does the filer report any securities sold in the past three months for ALNY?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Who is the broker handling the proposed sale in this Form 144?

UBS Financial Services, Inc., located at 11 Madison Avenue, 4th Floor, New York, NY 10010.